Citius Oncology Shares Rise After Cancer Treatment Launches

Dow Jones

Yesterday

By Katherine Hamilton

Citius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin.

The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year.

Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday.

A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months.

Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said.

Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 01, 2025 12:43 ET (17:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588772937"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588772937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588772937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 01:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588772937","market":"sg","top_or_hot":-1,"title":"Citius Oncology Shares Rise After Cancer Treatment Launches","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin. \n</p>\n<p>\n  The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year. \n</p>\n<p>\n  Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday. \n</p>\n<p>\n  A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months. \n</p>\n<p>\n  Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said. \n</p>\n<p>\n  Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 01, 2025 12:43 ET (17:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Shares Rise After Cancer Treatment Launches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Shares Rise After Cancer Treatment Launches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-02 01:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin. \n</p>\n<p>\n  The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year. \n</p>\n<p>\n  Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday. \n</p>\n<p>\n  A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months. \n</p>\n<p>\n  Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said. \n</p>\n<p>\n  Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 01, 2025 12:43 ET (17:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTOR","symbol_name":"CITIUS ONCOLOGY INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2588772937","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588772937","pubTimestamp":1764610980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Citius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin.The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year.Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday.A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months.Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said.Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTOR":"CITIUS ONCOLOGY INC","BK4139":"生物科技"},"translate_title":"癌症治疗推出后Citius Oncology股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTOR":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\nCitius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin. \n\n\n  The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year. \n\n\n  Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday. \n\n\n  A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months. \n\n\n  Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said. \n\n\n  Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 12:43 ET (17:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}